|
|
Home > ȸ»ç¼Ò°³ > ´ëÇ¥ÀÌ»ç Àλ縻 |
|
¾È³çÇϽʴϱî,
 |
´ëÇ¥ÀÌ»ç ÀåÇü¼® |
APVS¿¡ ¿À½Å°É ȯ¿µÇÕ´Ï´Ù. APVS´Â Çѱ¹ Á¦¾à»ê¾÷ÀÇ ¼ºÀå¿¡ µû¸¥ °ßÀÎÂ÷ ¿ªÇÒÀ» ÇϰíÀÚ ÇÕ´Ï´Ù. ½ÇÇè±â±â ¹× ¼³ºñµéÀÌ ´Ã¾î³ª°í º¸´Ù ÀÚµ¿ÈµÇ¸é¼,
¾àÀÇ Ç°ÁúÀ» À¯ÁöÇϱâ À§ÇÑ ÄÄÇ»ÅÍ ½Ã½ºÅÛ ¹ë¸®µ¥À̼ÇÀÇ Çʿ伺ÀÌ º¸´Ù Áõ´ëµÇ¾ú½À´Ï´Ù. APVS´Â ¹Ì±¹ÀÇ Á¦¾à ¹ë¸®µ¥ÀÌ¼Ç °æÇèÀ» Çѱ¹¿¡ Àß Á¶È½ÃÄÑ
Á¦¾à»ê¾÷°ú ¿©·¯ºÐÀÇ ºñÁî´Ï½º¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â ÃÖ»óÀÇ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ °ÍÀÔ´Ï´Ù.
APVS´Â Çѱ¹ »ê¾÷ ¹× ±Ù·ÎÀÚµé°úÀÇ ¸¸³²À» ÅëÇÏ¿© ¹ë¸®µ¥À̼ÇÀÇ ¼öÇà ¹æ¹ý°ú ÀÌÇØ¸¦ ³ÐÈ÷°íÀÚ ÇÕ´Ï´Ù. APVS´Â ¹Ì±¹¿¡¼ °ú°Å ½ÃÇàÂø¿À¿Í °æÇèµéÀ»
ÅëÇÏ¿© ¿À·§µ¿¾È ¹ßÀüµÇ¾î¿Â ¹ë¸®µ¥ÀÌ¼Ç ¹æ¹ýµéÀ» Çѱ¹¿¡ Àü´ÞÇϰڽÀ´Ï´Ù.
APVS´Â Çѱ¹ÀÌ ¾Æ½Ã¾Æ¿¡¼ Á¦¾à¾÷°è¿Í »ý¸í°øÇÐ °³¹ßÀÇ Áß½ÉÀÌ µÉ °ÍÀ̶ó È®½ÅÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î Çѱ¹ÀÇ ¼öÇаú °úÇÐ ±â¼úÀÌ ³ôÀº ¼öÁØ¿¡ ¿Í ÀÖ´Ù´Â
°ÍÀ» ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. À̰ÍÀº Çѱ¹ÀÇ ±â¼ú¼ºÀå, ¿ì¼öÇÑ ¾÷¹«´É·Â ±×¸®°í ¹Ì±¹°úÀÇ ¿Ü±³°ü°è¸¦ ÅëÇÑ Á¦¾à»ê¾÷ÀÇ ºü¸¥ ¼ºÀåÀ» °¡Á®¿Ã °ÍÀÔ´Ï´Ù.
Àú´Â ¹Ì±¹ÀÇ MIT °ø´ë¿¡¼ ÄÄÇ»ÅÍ °øÇÐÀ» Àü°øÇß½À´Ï´Ù. ±× ÀÌÈÄ ÄÄÇ»ÅÍ ½Ã½ºÅÛ ¹× Á¦¾à ¹ë¸®µ¥ÀÌ¼Ç ¾÷¹«¿¡ Á¾»çÇßÀ¸¸ç, LIMS, DCS & Web ±â¹ÝÀÇ
ÀÓ»ó½ÇÇè ¼ÒÇÁÆ®¿þ¾î, ÀÚµ¿È ½Ã½ºÅÛÀ» Æ÷ÇÔÇÏ¿© Æø³Ð°í ´Ù¾çÇÑ ÄÄÇ»ÅÍ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¾÷¹« °æÇèÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Àú´Â Johnson & Johnson,
GlaxoSmithKline, Bayer, Aventis¿Í Schering-Plough µîÀÇ ´ë±â¾÷À» Æ÷ÇÔÇÏ¿© ¸¹Àº ȸ»çµéÀÇ ÄÁ¼³ÆÃ ¾÷¹«¸¦ ¼öÇàÇß½À´Ï´Ù. APVS Korea ¶ÇÇÑ »ý»ê,
½ÇÇè, Ŭ¸®´×, °øÁ¤ & ¼³ºñºÐ¾ßÀÇ ¹ë¸®µ¥ÀÌ¼Ç Àü¹®°¡µé°ú, Àü¹®±â¼ú ¹× dzºÎÇÑ Áö½ÄÀ» °®Ãá ¹Ì±¹ ÄÁ¼³ÅÏÆ®µéÀÇ Áö¿øÀ» ¹Þ°Ô µÉ °ÍÀÔ´Ï´Ù. ÀÌ¿Í
°°Àº ¹Ì±¹ÀÇ °æÇè°ú ´õºÒ¾î, Çѱ¹ Á¦¾àȸ»ç Ãâ½ÅÀÇ APVS Korea Á÷¿øµµ Ź¿ùÇÑ ±â¼ú°ú °æÇèÀ» °âºñÇϰí ÀÖ½À´Ï´Ù.
APVS´Â ½Å±Ô ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀå °³¹ßÀ» µµ¿ï °ÍÀÔ´Ï´Ù. APVS°¡ ¼öÇàÇÏ´Â Validation ¼ºñ½º´Â Á¦¾à ȸ»çµéÀÌ ¾ÈÀüÇϰí, º¸´Ù ½Å·ÚÇÒ ¼ö ÀÖ´Â Á¦Ç°µéÀ»
»ý»êÇϴµ¥ µµ¿òÀÌ µÉ °ÍÀ̶ó´Â °ÇÑ ¹ÏÀ½À» °¡Áö°í ÀÖ½À´Ï´Ù.
APVS´Â Á¦¾à ¹× »ý¸í°øÇÐ ¹ßÀü°ú ¼ºÀåÀÇ Â÷ÈÄ ±â¼úÀ» ¼±µµÇÒ, º¸´Ù ³ªÀº Çѱ¹ °Ç¼³¿¡ ¸ðµÎ°¡ ¾ÕÀå¼¶À¸·Î½á ´Ù°¡¿Ã ¹Ì·¡¿¡ µµÀü°ú º¸»óÀ» ±â´ëÇÕ´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
|
|
Hello,
Welcome to APVS Korea. As the Korean pharmaceutical industry grows, we want to be part of it. As labs and facilities grow and become more
automated, there is more of a need for computer system validation in order to maintain the quality of the drug products. We combine the
experience of pharmaceutical validation in the U.S. with the business practices of Korea to bring you the best validation solutions for
your company and for the Korean pharmaceutical industry.
I want to improve the understanding and implementation practices of validation throughout the industry and the Korean work force. I want to
teach the validation practices that have been developed in the U.S. over many decades so that, in Korea, we can learn from the past mistakes
and experiences of others.
I foresee that Korea will be a center for pharmaceutical and biotechnology development in Asia. Korea has been recognized as having the
strongest math and science skills in the world. This, along with its technological advancements, strong work habits, and diplomatic
relations with the U.S., make Korea a fertile region for the rapid growth of its pharmaceutical industry.
My background includes a Masters degree in Computer Engineering from MIT. Since then, I have worked with computer systems and
pharmaceutical validation. I have worked with a wide variety of computer systems including automated equipment, LIMS, DCS, and
web-based clinical trial software. I have consulted for large companies including, Johnson & Johnson, GlaxoSmithKline, Bayer,
Aventis, and Schering-Plough. APVS Korea is also supported by the expertise and knowledgebase of other U.S. consultants, experts
in validation in fields such as manufacturing, labs, cleaning, process, and facility. In addition to the U.S. experience, our
staff brings a great deal of skills and experience from Korean pharmaceutical companies.
I am honored to be able to bring my knowledge and experience of pharmaceutical computer system validation from the U.S. to help develop
the emerging validation market in South Korea. I believe strongly in the role that validation plays to help pharmaceutical companies
make safer, more reliable products.
I look forward to the challenges and rewards in the coming years as we all work together to build a better Korea, one that marches
forward strongly to the next technological forefront of pharmaceutical and biotechnology advancement and growth.
Sincerely,
|
|
|
|
|